Results from the Phase 2 trial of the DAR-901 tuberculosis (TB) vaccine from a three-year trial in Tanzania were announced by investigators at Dartmouth’s Geisel School of Medicine and published in the journal Vaccine.
Results from the Phase 2 trial of the DAR-901 tuberculosis (TB) vaccine from a three-year trial in Tanzania were announced by investigators at Dartmouth’s Geisel School of Medicine and published in the journal Vaccine.
This page may link to PDF files. Use this link to download Adobe Reader if needed.